We further benchmarked TRTpred in four distinct CD8+ TILs datasets from different tumor indications (ref. 14, melanoma; ref. 12, lung; ref. 8, pan-cancer; ref. 11, gastrointestinal (GI); Supplementary Table 1). Here, CD8A is linked to neoplasm.